mTOR inhibitors: changing landscape of endocrine-resistant breast cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR inhibitors: changing landscape of endocrine-resistant breast cancer
Authors
Keywords
-
Journal
Future Oncology
Volume 10, Issue 3, Pages 443-456
Publisher
Future Medicine Ltd
Online
2014-02-24
DOI
10.2217/fon.13.178
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy
- (2017) Gary R. Hudes et al. Journal of the National Comprehensive Cancer Network
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients
- (2012) E. E. W. Cohen et al. CLINICAL CANCER RESEARCH
- Hedgehog Overexpression Is Associated with Stromal Interactions and Predicts for Poor Outcome in Breast Cancer
- (2011) S. A. O'Toole et al. CANCER RESEARCH
- Functional Activation of the Estrogen Receptor- and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
- (2011) G. J. Sabnis et al. CANCER RESEARCH
- High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
- (2011) Paige Yellen et al. CELL CYCLE
- Aromatase, aromatase inhibitors, and breast cancer
- (2011) Saranya Chumsri et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
- (2011) M. Dowsett et al. JNCI-Journal of the National Cancer Institute
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
- (2010) Dorothy A. White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E
- (2010) Andrew C. Hsieh et al. CANCER CELL
- New Strategies in Estrogen Receptor-Positive Breast Cancer
- (2010) S. R. D. Johnston CLINICAL CANCER RESEARCH
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- mTOR: from growth signal integration to cancer, diabetes and ageing
- (2010) Roberto Zoncu et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- mTORC1-Mediated Cell Proliferation, But Not Cell Growth, Controlled by the 4E-BPs
- (2010) R. J. O. Dowling et al. SCIENCE
- PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer
- (2009) R. J. Crowder et al. CANCER RESEARCH
- Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin
- (2009) K. Yu et al. CANCER RESEARCH
- mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation
- (2009) Rachel L. Yamnik et al. FEBS LETTERS
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Palomid 529, a Novel Small-Molecule Drug, Is a TORC1/TORC2 Inhibitor That Reduces Tumor Growth, Tumor Angiogenesis, and Vascular Permeability
- (2008) Q. Xue et al. CANCER RESEARCH
- Phosphorylation at serines 104 and 106 by Erk1/2 MAPK is important for estrogen receptor-α activity
- (2008) Ross S Thomas et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin
- (2008) A. Toschi et al. MOLECULAR AND CELLULAR BIOLOGY
- Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases
- (2008) Beth Apsel et al. Nature Chemical Biology
- The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
- (2007) Ahmad Awada et al. EUROPEAN JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search